SCHEMBL3911615

SCHEMBL3911615

Cc1cc(Cl)cc(Cl)c1S(=O)(=O)Nc1ccc2c(c1)c(=O)[nH]n2Cc1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 1/20 0.40
NR1I2 O75469 1/20 0.36
PKM P14618 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.36
IDH1 O75874 1/20 0.36
PTGDR2 Q9Y5Y4 3/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TBXAS1 P24557 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GLA P06280 1/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
ERAP1 Q9NZ08 1/20 0.34
HTR6 P50406 2/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3909837 0.94 PFKFB3 (0.40) PFKFB3NR1I2PKMSMN1; SMN2TP53
SCHEMBL1811082 0.91 NR1I2 (0.46) PFKFB3NR1I2TP53MEN1KMT2A
SCHEMBL3913049 0.82 PFKFB3 (0.41) PFKFB3NR1I2PKMSMN1; SMN2TP53
SCHEMBL3904611 0.82 PFKFB3 (0.42) PFKFB3NR1I2TAS2R14HTR6MAPT
SCHEMBL1811639 0.82 PTGDR2 (0.48) PKMSMN1; SMN2TP53PTGDR2MEN1
SCHEMBL3917152 0.82 LMNA (0.36) NR1I2PKMSMN1; SMN2TP53IDH1
SCHEMBL3906691 0.81 PFKFB3 (0.40) PFKFB3NR1I2PKMSMN1; SMN2TP53
SCHEMBL3918595 0.81 GSPT1 (0.42) NR1I2PKMSMN1; SMN2TP53TAS2R14
SCHEMBL3904637 0.80 BRD4 (0.50) PKMSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL3910618 0.80 SGK1 (0.41) NR1I2PKMSMN1; SMN2TP53PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US claimed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP claimed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US claimed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP disclosed
EP-1797042-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-06-20 EP disclosed
WO-2006034804-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-04-06 WO disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 PFKFB3 2136/4885NR1I2 79/4885PKM 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.